Clinical Trial Update: To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating PEG-rhG-CSF (Jinyouli) for reducing chemotherapy-induced neutropenia in cervical cancer, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Jinyouli (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Air Force Military Medical University, China | Conditions: Cervical Cancer | Phase 4 | Status: UNKNOWN